Suppr超能文献

使用基于细胞的高通量筛选试验鉴定新型人类高密度脂蛋白受体上调剂。

Identification of novel human high-density lipoprotein receptor Up-regulators using a cell-based high-throughput screening assay.

作者信息

Yang Yuan, Zhang Zhongbing, Jiang Wei, Gao Lei, Zhao Guiyu, Zheng Zhihui, Wang Min, Si Shuyi, Hong Bin

机构信息

School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.

出版信息

J Biomol Screen. 2007 Mar;12(2):211-9. doi: 10.1177/1087057106297568. Epub 2007 Jan 26.

Abstract

Scavenger receptor class B type I (SR-BI) is the high-affinity high-density lipoprotein (HDL) receptor, and CLA-1 is the human homologue of the murine SR-BI. CLA-1/SR-BI receptor has been suggested as a new preventative and/or therapeutic target for atherosclerosis due to its pivotal role in overall HDL cholesterol (HDL-C) metabolism and its antiatherogenic activity in vivo. To search for active compounds that can increase CLA-1 transcription, a novel cell-based assay was developed for application in high-throughput screening (HTS). Human hepatoma HepG2 cells were transfected with a CLA-1-promoter-luciferase reporter gene construct, and the stable transfected cell line was selected and named CLAp-LUC HepG2. With rosiglitazone as a positive control, this stable cell line was used to establish a specific CLA-1 gene expression assay in a 96-well microplate format. The evaluating parameter Z' value of 0.64 showed that this cell-based HTS assay was robust and reliable. Screening of 6000 microbial secondary metabolite crude extracts identified 8 positive strains. Between 2 identified CLA-1 up-regulators produced by actinomycete strain 04-4776, 4776B may stimulate not only the expression of CLA-1 on the transcriptional and translational levels but also the activity of CLA-1 to uptake the HDL-C in HepG2 cells. The active compounds originated from this HTS assay may be developed to drug candidates or lead compounds for new antiatherosclerosis agents.

摘要

I型清道夫受体B类(SR-BI)是高亲和力高密度脂蛋白(HDL)受体,而CLA-1是小鼠SR-BI的人类同源物。CLA-1/SR-BI受体因其在整体HDL胆固醇(HDL-C)代谢中的关键作用及其体内抗动脉粥样硬化活性,已被认为是动脉粥样硬化的新预防和/或治疗靶点。为了寻找可增加CLA-1转录的活性化合物,开发了一种基于细胞的新检测方法用于高通量筛选(HTS)。用CLA-1启动子-荧光素酶报告基因构建体转染人肝癌HepG2细胞,选择稳定转染的细胞系并命名为CLAp-LUC HepG2。以罗格列酮作为阳性对照,该稳定细胞系用于在96孔微孔板中建立特定的CLA-1基因表达检测方法。评估参数Z'值为0.64表明该基于细胞的HTS检测方法稳健可靠。对6000种微生物次生代谢物粗提物的筛选鉴定出8株阳性菌株。在由放线菌菌株04-4776产生的2种已鉴定的CLA-1上调因子中,4776B不仅可能在转录和翻译水平上刺激CLA-1的表达,还可能刺激CLA-1在HepG2细胞中摄取HDL-C的活性。源自该HTS检测方法的活性化合物可能被开发为新抗动脉粥样硬化药物的候选药物或先导化合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验